Creighton University School of Medicine-Phoenix Obstetrics and Gynecology

Topics

• Endometrial and Cervical Cancer Treatments 173
• Ovarian cancer diagnosis and treatment 169
• Cervical Cancer and HPV Research 61
• PARP inhibition in cancer therapy 54
• Endometriosis Research and Treatment 43
• Preterm Birth and Chorioamnionitis 26
• Uterine Myomas and Treatments 23
• Gestational Diabetes Research and Management 20
• Pregnancy and preeclampsia studies 20
• Reproductive Biology and Fertility 18
• Gynecological conditions and treatments 16
• Reproductive Health and Contraception 16

Most cited

1. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.

   The New England journal of medicine · 2023 · 703 citations · Bradley Monk

2. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.

   The New England journal of medicine · 2021 · 855 citations · Bradley Monk

3. Survival with Cemiplimab in Recurrent Cervical Cancer.

   The New England journal of medicine · 2022 · 385 citations · Bradley Monk

4. Endometriosis Typology and Ovarian Cancer Risk.

   JAMA · 2024 · 129 citations · Matthew Peterson

5. Treatment advances across the cervical cancer spectrum.

   Nature reviews. Clinical oncology · 2025 · 96 citations · Bradley Monk

6. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022 · 358 citations · Bradley Monk

7. First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.